Pharma BD Deal Intelligence
Celera abandoned the small-molecule drug-discovery strategy Axys was bought to build within 4 years, then sold off the chemistry, including what became blockbuster Imbruvica, for a token sum
Full analysis, sources & comparables →Merger expected to advance drug discovery capabilities for Celera... The capabilities expected to be acquired through this merger should support and accelerate…
Analyst quoted on the deal: "Building a platform takes a long, long time"—framing the Axys buy as a faster route into drug discovery for Celera than internal…
Despite ~$864M in cash and the Axys-driven pivot, Celera shares fell from $256 to ~$14 as investors questioned whether genomic data alone—even with Axys…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Stock-for-stock ~$174M at $4.65/Axys share. Strategic pivot for Celera into therapeutics/drug discovery.
Celera abandoned the small-molecule drug-discovery strategy Axys was bought to build within 4 years, then sold off the chemistry, including what became blockbuster Imbruvica, for a token sum
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celera Genomics Group / Axys Pharmaceuticals Inc. (this deal) | 2001 | $173M | 23 |
| Celera Genomics Group / Paracel Inc. | 2000 | $245M | 10 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals